Journal of Modern OncologyJournal of Modern Oncology1815-14341815-1442LLC Obyedinennaya Redaktsiya27051Research ArticleRare morphological forms of breast cancer: features of surgical approachVysotskayaI Vvysotskaya.irina@mail.ruLetyaginV P-KolyadinaI V-MartynovaG V-I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian FederationN.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian FederationRussian Medical Academy of Postgraduate Education of the Ministry of Health of the Russian Federation15032016181454909042020Copyright © 2016, Consilium Medicum2016In accordance with WHO recommendations among the epithelial tumors of breast carcinomas made selection of rare histological subtypes. It is diverse, poorly studied and prognostically heterogeneous group of breast cancer. This situation is related to the rarity of their occurrence in the breast cancer population - from several tens to individual cases, which leads to the inability to obtain statistically valid conclusions. This concerns both the clinical and prognostic features and treatment strategy. Optimal control of local approaches in infiltrative ductal and lobular form of breast cancer are well understood, defined the standard surgery and indications for it. Somewhat different is the situation in the case of rare histological types of breast cancer, in which this problem is the subject of research.breast cancerrare histological types of breast cancerbreast conserving surgeryradical mastectomysentinel lymph node biopsyрак молочной железыредкие гистологические типы рака молочной железыорганосохраняющее лечениерадикальная мастэктомиябиопсия сторожевого лимфоузла[Мартынова Г.В. Редкие формы рака молочной железы. Лечение и прогноз. Дис. … канд. мед. наук. М., 2009.][Высоцкая И.В., Ермилова В.Д., Летягин В.П. и др. Клинические и морфологические особенности редких гистологических типов рака молочной железы. М.: АБВ-пресс, 2011.][Портной С.М.. Рак молочной железы (факторы прогноза и лечение). Дис. … д - ра мед. наук. М., 1998.][Колядина И.В. Локальные рецидивы первично - операбельного рака молочной железы. Дис. … канд. мед. наук. М.: 2009.][Vu-Nishino H, Tavassoli F.A, Ahrens W.A et al. Clinicopathologic features and long - term outcome of patients with medullary breast carcinoma managed with breast - conserving therapy (BCT). Int J Radiat Oncol Biol Phys 2005; 62: 1040-7.][Cheang M.C et al. Basal - like breast cancer defined by five biomarkers has superior prognostic value than triple - negative phenotype. Clin Cancer Res 2008; 14: 1368-76.][Cremoux P et al. p53 mutation as a genetic trait of typical medullary breast carcinoma. J Natl Cancer Inst 1999; 91: 641-3.][Xu R, Feiner H et al: Differential amplification and overexpression of HER-2/neu, p53, MIB1, and estrogen receptor/progesterone receptor among medullary carcinoma, atypical medullary carcinoma, and high - grade invasive ductal carcinoma of breast. Arch Pathol Lab Med 2003; 127: 1458-64.][A-Yong Cao, Min He, Liang Huang. Clinicopathologic characteristics at diagnosis and the survival of patients with medullary breast carcinoma in China: a comparison with infiltrating ductal carcinoma - not otherwise specified. World J Surgic Oncol 2013; 11: 91][Richardson W.W. Medullary carcinoma of the breast; a distinctive tumour type with a relatively good prognosis following radical mastectomy. Br J Cancer 1956; 10: 415-23.][Terando A.M et al. Treatment and prognosis of Rare Breast Cancer. Ann Surg Oncol 2015; 14: 1268-79.][Vranic S, Bender R, Palazzo J et al. A review of adenoid cystic carcinoma of the breast with emphasis on its molecular and genetic characteristics. Hum Pathol 2013; 44: 301-9.][Vranic S, Tawfik O, Palazzo J et al. EGFR and HER-2/neu expression in invasive apocrine carcinoma of the breast. Mod Pathol 2010; 23: 644-53.][Dellapasqua S, Maisonneuve P, Viale G et al. Immunohistochemically defined subtypes and outcome of apocrine breast cancer. Clin Breast Cancer 2013;13: 95-102.][Montagna E, Maisonneuve P, Rotmensz N et al. Heterogeneity of triple - negative breast cancer: Histologic subtyping to inform the outcome. Clin Breast Cancer 2013; 13: 31-9.][Chen L, Fan Y, Lang R.G et al. Heterogeneity of micropapillary breast cancer: prognosis and outcomes. Int J Surg Pathol 2008; 16: 155-63.][Jacobs M, Fan F, Tawfik O. Clinicopathologic and biomarker analysis of invasive pleomorphic lobular carcinoma as compared with invasive classic lobular carcinoma: an experience in our institution and review of the literature. Ann Diagn Pathol 2012; 16:185-189][Jung H.N, Shin J.H, Han B.K et al. Are the imaging features of the pleomorphic variant of invasive lobular carcinoma different from classic ILC of the breast? Breast 2013; 22: 324-9.][Hennessy et al. Biphasic metaplastic sarcomatoid carcinoma of the breast. Ann Oncol 2006; 17: 605-13.][Qing Hu, Wei-Xian Chen, Shan-Liang Zhong et al. Current Progress in the Treatment of Metaplastic Breast Carcinoma. Asian Pacific J Cancer Prevent 2013; 14: 6221-5.][Sebolt-Leopold. Development of anticancer drugs targeting the MAP kinase pathway. Oncogene 2000; 19: 6594-9.][Shah D.R, Tseng W.H, Martinez S.R. Treatment Options for Metaplastic Breast Cancer Oncol 2012; 2012: 706162.][Pezzi C.M et al. Metaplastic Breast Cancer. Breast Cancer Res Treat 2012; 131 (1): 10.1007/s10549-011-1393-6.][Chao T.C et al. Metaplastic carcinomas of the breast. J Surg Oncol 1999; 71: 220-5.]